Eric P Davidson1, Lawrence J Coppey, Hanna Shevalye, Alexander Obrosov, Randy H Kardon, Mark A Yorek. 1. *Department of Internal Medicine, University of Iowa, Iowa City, IA;†Department of Veterans Affairs Iowa City Health Care System, Iowa City, IA;‡Veterans Affairs Center for the Prevention and Treatment of Visual Loss, Iowa City, IA;§Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, IA; and¶Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa City, IA.
Abstract
PURPOSE: This study investigated the efficacy of monotherapy versus combination of menhaden oil, α-lipoic acid, and enalapril on corneal sensation and morphometry and other neuropathy-related endpoints in a rat model of type 2 diabetes. METHODS: Male Sprague-Dawley rats (aged 12 weeks) were fed a high-fat diet for 8 weeks followed by 30 mg/kg streptozotocin. After 16 weeks of hyperglycemia, 12-week treatments consisting of menhaden oil, α-lipoic acid, enalapril, or their combination were initiated. Before and after treatments, we performed analyses of multiple neural and vascular endpoints including corneal sensitivity, corneal nerve density, vascular reactivity of epineurial arterioles, motor and sensory nerve conduction velocity, intraepidermal nerve fiber density, and thermal nociception. RESULTS: Before treatment, all the neural and vascular endpoints in diabetic rats were impaired. Treating diabetic rats with monotherapy was effective in improving neural and vascular deficits with menhaden oil being most efficacious. However, the combination therapy provided the greatest benefit and improved/reversed all nerve and vascular deficits. The effect of combination therapy on corneal relative sensitivity and structure (in mm/mm), primary endpoints for this study, for control, diabetic, and diabetic treated rats was 4.2 ± 1.4 and 7.5 ± 0.5, 12.1 ± 1.3* and 3.8 ± 0.2*, and 6.6 ± 2.3 and 7.3 ± 0.5, respectively (*P < 0.05 compared with control rats; P < 0.05 compared with diabetic rats). CONCLUSIONS: These studies suggest that a combination therapeutic approach may be most effective for treating vascular and neural complications of type 2 diabetes.
PURPOSE: This study investigated the efficacy of monotherapy versus combination of menhaden oil, α-lipoic acid, and enalapril on corneal sensation and morphometry and other neuropathy-related endpoints in a rat model of type 2 diabetes. METHODS: Male Sprague-Dawley rats (aged 12 weeks) were fed a high-fat diet for 8 weeks followed by 30 mg/kg streptozotocin. After 16 weeks of hyperglycemia, 12-week treatments consisting of menhaden oil, α-lipoic acid, enalapril, or their combination were initiated. Before and after treatments, we performed analyses of multiple neural and vascular endpoints including corneal sensitivity, corneal nerve density, vascular reactivity of epineurial arterioles, motor and sensory nerve conduction velocity, intraepidermal nerve fiber density, and thermal nociception. RESULTS: Before treatment, all the neural and vascular endpoints in diabeticrats were impaired. Treating diabeticrats with monotherapy was effective in improving neural and vascular deficits with menhaden oil being most efficacious. However, the combination therapy provided the greatest benefit and improved/reversed all nerve and vascular deficits. The effect of combination therapy on corneal relative sensitivity and structure (in mm/mm), primary endpoints for this study, for control, diabetic, and diabetic treated rats was 4.2 ± 1.4 and 7.5 ± 0.5, 12.1 ± 1.3* and 3.8 ± 0.2*, and 6.6 ± 2.3 and 7.3 ± 0.5, respectively (*P < 0.05 compared with control rats; P < 0.05 compared with diabeticrats). CONCLUSIONS: These studies suggest that a combination therapeutic approach may be most effective for treating vascular and neural complications of type 2 diabetes.
Authors: Irina G Obrosova; Fei Li; Omorodola I Abatan; Mark A Forsell; Katalin Komjáti; Pal Pacher; Csaba Szabó; Martin J Stevens Journal: Diabetes Date: 2004-03 Impact factor: 9.461
Authors: Matthew S Yorek; Eric P Davidson; Pieter Poolman; Lawrence J Coppey; Alexander Obrosov; Amey Holmes; Randy H Kardon; Mark A Yorek Journal: Invest Ophthalmol Vis Sci Date: 2016-05-01 Impact factor: 4.799
Authors: Brian Fink; Lawrence Coppey; Eric Davidson; Hanna Shevalye; Alexander Obrosov; Pratik Rajesh Chheda; Robert Kerns; William Sivitz; Mark Yorek Journal: Free Radic Res Date: 2020-04-24
Authors: Lawrence Coppey; Eric Davidson; Hanna Shevalye; Michael E Torres; Mark A Yorek Journal: Diabetes Metab Syndr Obes Date: 2018-04-09 Impact factor: 3.168
Authors: Laura J Andreasen; Rikke K Kirk; Christian Fledelius; Mark A Yorek; Jens Lykkesfeldt; Thorbjorn Akerstrom Journal: J Diabetes Res Date: 2020-08-02 Impact factor: 4.011